Study On The Relationship Between The Survival Time And The Expression Of EGFR, PR, ER, P53, HER2 And Clinical Stage

Objective:On completion of this offering, participants would be able to explain the relationship between the expression of EGFR, PR, ER, P53, HER2 and Clinical Stage of breast cancer patients. In the same time, we tried to provide the argument for estimating the prognosis and therapy in breast cancer if these markers could be approved significance to predict the prognosis. And then made a feasible study to investigate that the combination of these makers could enhance sensitivity and specialty.Method:We selected 185 samples and measured the expression of HER2, P53, ER, PR, EGFR in the way of IHC, and followed-up the survival time. Then to analyze the relationship of them by SPSS 10.0.Results:In 120 patients (64.9%) with complete followed-up data, 28 patients died (15%),with the record of the other 65 patients (35.1%) not available for this study. Immunohistochemical detection found that the positivity rates for HER2,P53,ER,PR, EGFR were 57.8%, 46.7%, 64.3%, 62.7%and 40.5% respectively in the total specimens examined.The clinical stage and the overexpression of HER2,P53,EGFR were in negative correlation with survival time in univariate analysis(Pclinical stage<0.01, PHER2<0.01, Pp53<0.01, PEGFR<0.01).OR of them were 2.154,1.556,1.772 and 2.046.While ER and PR,playing the protective role,were associated with a significant longer overall survival time(PER<0.01,PpR<0.01,ORER=0.416,ORpR=0.547).The correlation coefficient of HER2 and ER,HER2 and PR,ER and PR,HER2 and EGFR,HER2 and P53 were -0.343,-0.345,0.662,0.191and 0.291.The multivariate analysis suggested the combinations of HER2 and P53, HER2and EGFR were found significance to predict the prognosis. However,only PR expression was of significant prognostic value in the combinations of HER2 and PR(P=0.012, OR=0.614). Clinical stage and ER were showed significance to predict the prognosis in the combinations of HER2,ER and clinical stage. For the combinations of ER,PR,HER2,P53, EGFR and Clinical stage,Clinical stage and EGFR were significantly associated with unfavorable prognosis while the others were not. Conclusions:The expression of HER2 and ER,HER2 and PR, were showed negative correlation. Contrarily, the expression of ER and PR,HER2 and EGFR,HER2 and P53 were in positive correlation. Later clinical stage and the overexpression of HER2,P53, EGFR were related to poorly prognosis. However,the overexpression of ER and PR suggested a longer survival time and a better prognosis. EGFR, PR, ER, P53, HER2 and Clinical Stage were independent prognostic indicators of survival time in breast cancer. The combinations of HER2 and P53, HER2 and EGFR,EGFR and Clinical stage,ER and Clinical stage could enhance sensitivity and specialty in estimating the prognosis of breast cnacer.